Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Improving on Tail-of-the-Curve Evaluation With the American Society of Clinical Oncology Value Framework

Improving on Tail-of-the-Curve Evaluation With the American Society of Clinical Oncology Value... Letters Stephen G. Chun, MD 5-year overall survival ; consequently, it is also accredited Todd A. Pezzi, MD, MBA grade A for curative potential and the final ESMO-MCBS v1.1 David L. Schwartz, MD score is recorded as both A and 4. We welcome further external review of the capacity of Author Affiliations: Division of Radiation Oncology, University of Texas MD ESMO-MCBS v1.1 to evaluate immunotherapy trials, and we Anderson Cancer Center, Houston (Chun, Pezzi, Schwartz); Department of hope that Ben-Aharon and colleagues will undertake this Radiation Oncology, University of Tennessee Health Science Center, Memphis challenge. (Schwartz). Corresponding Author: Stephen G. Chun, MD, Division of Radiation Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Nathan I. Cherny, MBBS, FRACP, FRCP, LLD TX 77030 (sgchun@mdanderson.org). Elisabeth G. E. de Vries, MD, PhD Published Online: August 2, 2018. doi:10.1001/jamaoncol.2018.3292 For the European Society for Medical Oncology Magnitude Conflict of Interest Disclosures: None reported. of Clinical Benefit Scale Working Group 1. Pezzi TA, Schwartz DL, Mohamed ASR, et al. Barriers to combined-modality therapy for limited-stage small cell lung cancer [published online January 4, Author Affiliations: Cancer Pain and Palliative Medicine Service, Department of 2018]. JAMA Oncol. doi:10.1001/jamaoncol.2017.4504 Medical Oncology, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Improving on Tail-of-the-Curve Evaluation With the American Society of Clinical Oncology Value Framework

Loading next page...
 
/lp/american-medical-association/improving-on-tail-of-the-curve-evaluation-with-the-american-society-of-YOLeZ9Mwsj

References (5)

Publisher
American Medical Association
Copyright
Copyright 2018 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2018.3289
Publisher site
See Article on Publisher Site

Abstract

Letters Stephen G. Chun, MD 5-year overall survival ; consequently, it is also accredited Todd A. Pezzi, MD, MBA grade A for curative potential and the final ESMO-MCBS v1.1 David L. Schwartz, MD score is recorded as both A and 4. We welcome further external review of the capacity of Author Affiliations: Division of Radiation Oncology, University of Texas MD ESMO-MCBS v1.1 to evaluate immunotherapy trials, and we Anderson Cancer Center, Houston (Chun, Pezzi, Schwartz); Department of hope that Ben-Aharon and colleagues will undertake this Radiation Oncology, University of Tennessee Health Science Center, Memphis challenge. (Schwartz). Corresponding Author: Stephen G. Chun, MD, Division of Radiation Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Nathan I. Cherny, MBBS, FRACP, FRCP, LLD TX 77030 (sgchun@mdanderson.org). Elisabeth G. E. de Vries, MD, PhD Published Online: August 2, 2018. doi:10.1001/jamaoncol.2018.3292 For the European Society for Medical Oncology Magnitude Conflict of Interest Disclosures: None reported. of Clinical Benefit Scale Working Group 1. Pezzi TA, Schwartz DL, Mohamed ASR, et al. Barriers to combined-modality therapy for limited-stage small cell lung cancer [published online January 4, Author Affiliations: Cancer Pain and Palliative Medicine Service, Department of 2018]. JAMA Oncol. doi:10.1001/jamaoncol.2017.4504 Medical Oncology,

Journal

JAMA OncologyAmerican Medical Association

Published: Oct 16, 2018

There are no references for this article.